In oropharyngeal cancer, HPV status impacts distant mets risk

In oropharyngeal cancer, HPV status impacts distant mets risk
In patients with oropharyngeal cancer, human papillomavirus status and T and N staging categories affect the rate of distant control and may help identify candidates for treatment deintensification strategies, according to research published online Jan. 7 in the Journal of Clinical Oncology.
(HealthDay)—In patients with oropharyngeal cancer (OPC), human papillomavirus (HPV) status and T and N staging categories affect the rate of distant control (DC) and may help identify candidates for treatment deintensification strategies, according to research published online Jan. 7 in the Journal of Clinical Oncology.

Brian O'Sullivan, M.D., of the Princess Margaret Hospital/University of Toronto, and colleagues conducted a study involving 899 patients with OPC to identify patients with HPV-associated OPC who would be suitable for treatment deintensification strategies, that omit chemotherapy, based on their having a low risk of distant metastasis (DM).

Of the cohort, HPV status was ascertained for 505 patients, of which 382 were HPV-positive and 123 HPV-negative. During a median follow-up of 3.9 years, the researchers found that HPV-positive patients had significantly higher local and regional control but similar DC, compared with HPV-negative patients. HPV negativity, N2b-N3, T4, and alone were predictive of lower recurrence-free survival. HPV-positive patients were classified according to whether their risk of DM was low (T1-3N0-2c; DC, 93 percent) or high (N3 or T4; DC, 76 percent). HPV-negative patients were also classified into low (T1-2N0-2c; DC, 93 percent) and high DM risk (T3-4N3; DC, 72 percent) groups. In the HPV-positive, low-risk N2c subset, the DC rate was lower with treatment by alone (73 versus 92 percent for chemoradiotherapy).

"The of T and N categories on DM risk seems to be different for HPV-positive versus HPV-negative patients," the authors write. "A deintensification philosophy might be most optimally deployed in such subgroups with the least likelihood of DM."


Explore further

HPV improves survival for African-Americans with throat cancer

More information: Abstract
Full Text (subscription or payment may be required)
Editorial
Journal information: Journal of Clinical Oncology

Copyright © 2013 HealthDay. All rights reserved.

Citation: In oropharyngeal cancer, HPV status impacts distant mets risk (2013, January 14) retrieved 25 June 2019 from https://medicalxpress.com/news/2013-01-oropharyngeal-cancer-hpv-status-impacts.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more